558 related articles for article (PubMed ID: 32461092)
1. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
3. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
[TBL] [Abstract][Full Text] [Related]
4. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
5. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Nardone A; Weir H; Delpuech O; Brown H; De Angelis C; Cataldo ML; Fu X; Shea MJ; Mitchell T; Veeraraghavan J; Nagi C; Pilling M; Rimawi MF; Trivedi M; Hilsenbeck SG; Chamness GC; Jeselsohn R; Osborne CK; Schiff R
Br J Cancer; 2019 Feb; 120(3):331-339. PubMed ID: 30555156
[TBL] [Abstract][Full Text] [Related]
6. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
8. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
9. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
11. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER
Robertson JFR; Evans A; Henschen S; Kirwan CC; Jahan A; Kenny LM; Dixon JM; Schmid P; Kothari A; Mohamed O; Fasching PA; Cheung KL; Wuerstlein R; Carroll D; Klinowska T; Lindemann JPO; MacDonald A; Mather R; Maudsley R; Moschetta M; Nikolaou M; Roudier MP; Sarvotham T; Schiavon G; Zhou D; Zhou L; Harbeck N
Clin Cancer Res; 2020 Aug; 26(16):4242-4249. PubMed ID: 32234755
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Robertson JFR; Jiang Z; Di Leo A; Ohno S; Pritchard KI; Ellis M; Bradbury I; Campbell C
Breast Cancer; 2019 Nov; 26(6):703-711. PubMed ID: 31079343
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Shafaee MN; Ellis MJ
Future Oncol; 2018 Aug; 14(18):1789-1800. PubMed ID: 29783894
[TBL] [Abstract][Full Text] [Related]
16. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
17. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
18. Aromatase resistance mechanisms in model systems in vivo.
Brodie A; Macedo L; Sabnis G
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):283-7. PubMed ID: 19778610
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
20. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.
Nukatsuka M; Saito H; Noguchi S; Takechi T
In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]